news
Experiments with Marburg virus reveal novel antibody protective mechanisms
Researchers discovered the monoclonal antibodies of a convalescent Marburg infection patient bound to the glycoprotein and combatted infection in two novel ways.
List view / Grid view
Analysis
news
COVID-19 research indicates SARS-CoV-2 exploits immune defences to drive infection
A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.
news
Researchers release 21 openly available SARS-CoV-2 genome sequences
Austrian researchers reveal the first 21 SARS-CoV-2 viral genomes as part of their project to aid in international understanding of how the virus causing COVID-19 mutates.
article
Refreshing how we approach neuroscience with a novel screening technology
Drug Target Review discusses how NETSseq, a novel profiling technology, is bringing new insights to neurodegenerative and psychiatric diseases.
news
Organoids for the development of drugs and diagnostics for NASH
Organoids at different stages of non-alcoholic steatohepatitis (NASH) progression have been created to help in drug design and identification of diagnostic biomarkers.
news
Novel tuberculosis transport protein could be target of new treatments
Cryogenic electron microscopy revealed that the vitamin B12 transporter on Mycobacterium tuberculosis acts like a non-selective sluice, transporting both the vitamin and antibiotics.
news
FDA and BARDA to collaborate with Grifols on COVID-19 therapeutics
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.
article
Host pathways in coronavirus replication and COVID-19 pre-clinical drug target identification using proteomic and chemoinformatic analysis
The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains. Here, Joseph Steward highlights key findings of recent research.
article
How labs become AI ready with advanced informatics infrastructures
To reach the full potential of artificial intelligence (AI) in the pharma industry, it is essential that companies harmonise their data to remove the need for unnecessary human intervention. This article outlines how companies are working towards digital maturation and the obstacles they need to overcome to ensure the value…
article
Scientific data management: the core of quality
Gone are the days where mere data is considered king. We now understand the real value is in proper data management; but how best to harness its value? This article addresses current market options for companies wanting to extract every ounce of knowledge from raw data.
article
Expert view: Early product characterisation mitigates risks in biologics development
Developers of small molecule pharmaceuticals perform a battery of analytical tests before early clinical trials.
article
Expert view: Are you ready for next generation therapeutic antibodies?
Do not let the challenges of selecting and analysing bispecific antibodies create havoc in your antibody development.
news
UK Consortium to monitor spread and behaviour of coronavirus
The UK government has invested £20 million into the COVID-19 Genomics UK Consortium, which will use whole genome sequencing to inform infection control measures and therapeutic developments.
news
Novel phage display technique could lead to new peptide-based therapeutics
Researchers have shown that incorporating noncanonical amino acids (ncAAs) in phage display expands the range of peptides it can identify.
news
Developing a COVID-19 testing kit using RNA detection
The developers of an RNA imaging technology are using it to create a COVID-19 coronavirus testing kit, able to recognise the viral genome.